Speakers

Expand/Collapse

Peter Ellmark
Principal Scientist & Vice President - Discovery
Alligator Bioscience AB

Day One

Wednesday March 17th, 2021

11:45 am | Role of CD40 on Tumor Infiltrating Myeloid Cells in Immuno-Oncology

Victoria Smith
Chief Scientific Officer
Amphivena Therapeutics Inc.

Day One

Wednesday March 17th, 2021

1:45 pm | AMV564 Depletes MDSC & Activates T Cells in Cancer Patients

Kaiming Ye
Chair of the biomedical engineering department
Binghamton University

Day One

Wednesday March 17th, 2021

1:15 pm | Inducing Tumor Suppressive Microenvironments through Genome Edited CD47-/- Syngeneic Cell Vaccination

Michael Klichinsky
Co Founder & Vice President - Discovery Research
Carisma Therapeutics

Day Two

Thursday 18th March 2021

1:00 pm | Development of CAR Macrophages & CAR Monocytes for Solid Tumor Immunotherapy

Peter Lee
Professor and Chair, Dept. of Immuno-Oncology
City of Hope Comprehensive Cancer Center

Alex Swarbrick
Head of Laboratory
Garvan Institute of Medical Research

Day Two

Thursday 18th March 2021

3:00 pm | Novel Immune Populations in solid Cancers

Naval Daver
Assistant Professor - Department of Leukemia
MD Anderson Cancer Center

Caroline Bonnans
Associate Director of Research
Immune-Onc Therapeutics

Jessica Haverkamp
Senior Scientist
Merck & Co

Day Two

Thursday 18th March 2021

4:00 pm | Panel Discussion: What Role Will Myeloid Cell Biology & Therapeutics Play in Future Oncology Portfolios?

11:00 am | Modulation of Macrophage Pro-Tumor Functions in The Clinic

Daniel Getts
Chief Executive Officer
Myeloid Therapeutics

Day One

Wednesday March 17th, 2021

9:00 am | Panel Discussion: Reviewing the Past 12 Months of Progress in Understanding Myeloid Populations and their Role in Immunotherapy

Michele Gerber
Chief Medical Officer
Myeloid Therapeutics

Day One

Wednesday March 17th, 2021

4:15 pm | Harnessing Myeloid Cells to Kill Cancer & Alter The TME

Pushpa Jayaraman
Associate Director
Novartis

Day Two

Thursday 18th March 2021

11:30 am | Targeting TIM-3 and IL-1b in cancer immunotherapy: deciphering key roles on myeloid cells & pro-tumor inflammation in the TME

Barbara Platzer
Principal Scientist II
Novartis Institutes for BioMedical Research

Day One

Wednesday March 17th, 2021

9:00 am | Panel Discussion: Reviewing the Past 12 Months of Progress in Understanding Myeloid Populations and their Role in Immunotherapy

Lisa Coussens
Associate Director for Basic Research, Knight Cancer Institute
Oregon Health & Science University

Victor Levitsky
Chief Scientific Officer
Targovax

Day One

Wednesday March 17th, 2021

4:45 pm | Modulation of Tumor Microenvironment by Intra-Tumoral Delivery of ONCOS-102

Gael Roue
Head of the Lymphoma Translational Research Group
Josep Carreras Leukaemia Research Institute

Day Two

Thursday 18th March 2021

1:30 pm | Activity of the Novel Bispecific CD47-CD19 Antibody, TG-1801, In Preclinical Models of B-Cell Non-Hodgkin Lymphoma

Tatiana Novobrantseva
Chief Scientific Officer, Co-founder & Head of Research & Development
Verseau Therapeutics

Day One

Wednesday March 17th, 2021

2:45 pm | Reprogramming of Tumor Microenvironment Via Macrophage Modulators

Phuong Anh (Ani) Nguyen
Senior Scientist - Computational Biology
Verseau Therapeutics

Day Two

Thursday 18th March 2021

4:00 pm | Panel Discussion: What Role Will Myeloid Cell Biology & Therapeutics Play in Future Oncology Portfolios?

Ryan Phennicie
Senior Scientist - Immunology & Oncology Discovery
Generate Biomedicines

Day One

Wednesday March 17th, 2021

9:00 am | Panel Discussion: Reviewing the Past 12 Months of Progress in Understanding Myeloid Populations and their Role in Immunotherapy

Katherine Seid
Vice President Immunology Strategy
SQZ Biotech

Day Two

Thursday 18th March 2021

3:30 pm | TME Targeting Combination Strategies with SQZ PBMC-based Cancer Vaccine

Jo Van Ginderachter
Professor
Vrije University Brussels

Day Two

Thursday 18th March 2021

9:30 am | Inflammasome- & Gasdermin D-Independent IL-1β Production Mobilizes Neutrophils to Inhibit Antitumor Immunity

Yifan Zhan
Vice President for New Drug Research and Development
Huabo Biopharm

Day Two

Thursday 18th March 2021

9:00 am | Balancing GM-CSF Action in Tumour Myeloid Directed Immune Therapy

Gloria Lin
Associate Director of Translational Research
Trillium Therapeutics Inc.

 Lisa M. Coussens,
Professor and Chairwoman, Department of Cell, Developmental & Cancer Biology Associate Director for Basic Research, Knight Cancer Institute
Oregon Health & Science University

Day One

Wednesday March 17th, 2021

2:15 pm | Dynamic Interactions Between Myeloid and Lymphoid cells Regulate Response to Therapy in Solid Tumors

Stuart Hughes
Chief Executive Officer
Pathios Therapeutics

Stuart is Chief Executive Officer of Pathios and brings over 20 years experience in scientific leadership and drug discovery expertise. Stuart has worked across several therapeutic areas inlcuding CNS disorders, immunology and oncology and has deep expertise in guiding early stage drug discovery programs from inception toward clinical development. Stuart has gained wide-ranging experience from positions in both academic and industrial settings. Previous positions include Research Fellow and Senior Lecturer at Cardiff University, Principal Research Scientist at Eli Lilly and most recently, Senior Director at Vertex Pharmaceuticals. He holds a PhD in Neuroscience from Cardiff University.

Day One

Wednesday March 17th, 2021

3:45 pm | Identification of GPR65 As a Genetically-Validated, Innate Immune Checkpoint In Tumour Associated Macrophages And Discovery Of Potent And Selective GPR65 Antagonists